EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 2 (Février 2009) Med Sci (Paris), 25 2 (2009) 153-160 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 2, Février 2009
Page(s) 153 - 160
Section M/S revues
DOI https://doi.org/10.1051/medsci/2009252153
Published online 15 February 2009
  1. Campisi J, D’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8 : 729–40. [Google Scholar]
  2. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008; 8 : 450–8. [Google Scholar]
  3. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008; 20 : 150–5. [Google Scholar]
  4. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006; 66 : 2881–4. [Google Scholar]
  5. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23 : 2919–33. [Google Scholar]
  6. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007; 1775 : 5–20. [Google Scholar]
  7. Collado M, Serrano M. The senescent side of tumor suppression. Cell Cycle 2005; 4 : 1722–4. [Google Scholar]
  8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 : 57–70. [Google Scholar]
  9. Adams PD. Remodeling chromatin for senescence. Aging Cell 2007; 6 : 425–62. [Google Scholar]
  10. Narita M. Cellular senescence and chromatin organisation. Br J Cancer 2007; 96 : 686–91. [Google Scholar]
  11. Bischof O, Dejean A. SUMO is growing senescent. Cell Cycle 2007; 6 : 677–81. [Google Scholar]
  12. Sedivy JM. Telomeres limit cancer growth by inducing senescence: long-sought in vivo evidence obtained. Cancer Cell 2007; 11 : 389–91. [Google Scholar]
  13. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444 : 638–42. [Google Scholar]
  14. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444 : 633–7. [Google Scholar]
  15. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13 : 1549–56. [Google Scholar]
  16. Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004; 14 : 501–13. [Google Scholar]
  17. Reaper PM, di Fagagna F, Jackson SP. Activation of the DNA damage response by telomere attrition: a passage to cellular senescence. Cell Cycle 2004; 3 : 543–6. [Google Scholar]
  18. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 2002; 21 : 4338–48. [Google Scholar]
  19. Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008; 10 : 361–9. [Google Scholar]
  20. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436 : 642. [Google Scholar]
  21. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436 : 725–30. [Google Scholar]
  22. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436 : 720–4. [Google Scholar]
  23. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436 : 660–5. [Google Scholar]
  24. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007; 11 : 461–9. [Google Scholar]
  25. Guo X, Deng Y, Lin Y, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J 2007; 26 : 4709–19. [Google Scholar]
  26. Londono-Vallejo A, Lenain C, Gilson E. Cibler les télomères pour forcer les cellules cancéreuses à rentrer en sénescence. Med Sci (Paris) 2008; 24 : 383–9. [Google Scholar]
  27. Te Poele RH, Okorokov AL, Jardine L, et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62 : 1876–83. [Google Scholar]
  28. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445 : 656–60. [Google Scholar]
  29. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445 : 61–5. [Google Scholar]
  30. Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132 : 363–74. [Google Scholar]
  31. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8 : 877–84. [Google Scholar]
  32. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133 : 1019–31. [Google Scholar]
  33. Acosta JC, O’Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008; 133 : 1006–18. [Google Scholar]
  34. Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59 : 5002–11. [Google Scholar]
  35. Krtolica A, Campisi J. Integrating epithelial cancer, aging stroma and cellular senescence. Adv Gerontol 2003; 11 : 109–16. [Google Scholar]
  36. Liu D, Hornsby PJ. Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect. Neoplasia 2007; 9 : 418–26. [Google Scholar]
  37. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007; 67 : 3117–26. [Google Scholar]
  38. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120 : 513–22. [Google Scholar]
  39. Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 2008; 98 : 245–9. [Google Scholar]
  40. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22 : 4212–22. [Google Scholar]
  41. Sage J, Miller AL, Perez-Mancera PA, et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424 : 223–8. [Google Scholar]
  42. Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8 : 1291–7. [Google Scholar]
  43. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR. Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 2006; 6 : 25. [Google Scholar]
  44. Erenpreisa J, Cragg MS. Cancer: a matter of life cycle ? Cell Biol Int 2007; 31 : 1507–10. [Google Scholar]
  45. Gire V. La sénescence : une barrière télomérique à l’immortalité ou une réponse cellulaire aux stress physiologiques ? Med Sci (Paris) 2005; 21 : 491–7 [Google Scholar]
  46. Chien WW, Ffrench M. Régulation de p16INK4a, sénescence et oncogenèse. Med Sci (Paris) 2006; 22 : 865–71. [Google Scholar]
  47. Toledo F, Bluteau O, Simeonova I. Réactivation de p53 dans les tumeurs : une stratégie antitumorale prometteuse. Med Sci (Paris) 2007; 23 : 565–7. [Google Scholar]
  48. Gaumont-Leclerc MF, Ferbeyre G. Les cytokines préviennent les tumeurs via un mécanisme de sénescence cellulaire. Med Sci (Paris) 2009; 25 : 138–40. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.